Bio-Techne Corp (TECH): Price and Financial Metrics


Bio-Techne Corp (TECH)

Today's Latest Price: $318.43 USD

21.91 (-6.44%)

Updated Jan 27 4:00pm

Add TECH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

TECH Stock Summary

  • The price/operating cash flow metric for BIO-TECHNE Corp is higher than 91.71% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of -29.77%, BIO-TECHNE Corp's debt growth rate surpasses just 10.62% of about US stocks.
  • Over the past twelve months, TECH has reported earnings growth of 136.83%, putting it ahead of 90.42% of US stocks in our set.
  • Stocks that are quantitatively similar to TECH, based on their financial statements, market capitalization, and price volatility, are HZNP, MASI, AKAM, LOGI, and DT.
  • TECH's SEC filings can be seen here. And to visit BIO-TECHNE Corp's official web site, go to www.bio-techne.com.

TECH Stock Price Chart Interactive Chart >

Price chart for TECH

TECH Price/Volume Stats

Current price $318.43 52-week high $361.47
Prev. close $340.34 52-week low $155.17
Day low $317.69 Volume 194,300
Day high $336.60 Avg. volume 164,453
50-day MA $318.19 Dividend yield 0.38%
200-day MA $272.47 Market Cap 12.29B

Bio-Techne Corp (TECH) Company Bio


Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company was founded in 1976 and is based in Minneapolis, Minnesota.

TECH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$318.43$44.45 -87%

We started the process of determining a valid price forecast for BIO-TECHNE Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that BIO-TECHNE Corp ranked in the 14th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 87%. The most interesting components of our discounted cash flow analysis for BIO-TECHNE Corp ended up being:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 97. Its equity weight surpasses that of 78.16% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 12.7% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • TECH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 47.06% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-87%
1%-87%
2%-87%
3%-87%
4%-87%
5%-87%

Want more companies with a valuation profile/forecast similar to that of BIO-TECHNE Corp? See ENDP, MOH, RSCF, ZBH, and ZYXI.


TECH Latest News Stream


Event/Time News Detail
Loading, please wait...

TECH Latest Social Stream


Loading social stream, please wait...

View Full TECH Social Stream

Latest TECH News From Around the Web

Below are the latest news stories about BIO-TECHNE Corp that investors may wish to consider to help them evaluate TECH as an investment opportunity.

Mesenchymal Stem Cells Market Analysis By Main Players Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH,

The “Mesenchymal Stem Cells Market” Research Report 2020-2027 is a specialized and in-depth study of the Mesenchymal Stem Cells industry with a focus on the global market trend. The report aims to provide an overview of global Mesenchymal Stem Cells

OpenPR | January 25, 2021

Bio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at 8:00 a.m. CST to review second quarter 2021 financial results.

Yahoo | January 14, 2021

The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia ...

Benzinga | December 29, 2020

Is TECH A Good Stock To Buy According To Hedge Funds?

With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Bio-Techne Corporation (NASDAQ:TECH). Is TECH a good stock to buy? […]

Yahoo | December 21, 2020

Bio-Techne To Present At The 39th Annual J.P. Morgan Healthcare Conference

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Yahoo | December 21, 2020

Read More 'TECH' Stories Here

TECH Price Returns

1-mo 1.12%
3-mo 26.29%
6-mo 15.99%
1-year 47.13%
3-year 128.66%
5-year 302.38%
YTD 0.28%
2020 45.40%
2019 52.67%
2018 12.60%
2017 27.40%
2016 15.77%

TECH Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TECH Dividend History

Continue Researching TECH

Want to see what other sources are saying about BIO-TECHNE Corp's financials and stock price? Try the links below:

BIO-TECHNE Corp (TECH) Stock Price | Nasdaq
BIO-TECHNE Corp (TECH) Stock Quote, History and News - Yahoo Finance
BIO-TECHNE Corp (TECH) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0649 seconds.